RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies

By Yu Ke-Da  

Breast Cancer Research and Treatment, Vol. 126, Iss. 2, 2011-04 ,pp. : 365-371

Springer Publishing Company

Access to resources Recommend Favorite

Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene

By Ticha Ivana  

Breast Cancer Research and Treatment, Vol. 124, Iss. 2, 2010-11 ,pp. : 337-347

Springer Publishing Company

Access to resources Recommend Favorite

Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age

By Kolk Dorina  

Breast Cancer Research and Treatment, Vol. 124, Iss. 3, 2010-12 ,pp. : 643-651

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer

By Reding Kerryn  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 491-498

Springer Publishing Company

Access to resources Recommend Favorite

High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer

By Aceto Gitana  

Breast Cancer Research and Treatment, Vol. 122, Iss. 3, 2010-08 ,pp. : 671-683

Springer Publishing Company

Access to resources Recommend Favorite